Repurposed Anti‑Inflammatory Medications in Enhancing Chemotherapy Response

Introduction

Inflammation is a hallmark of cancer, driving initiation, promotion, invasion and metastasis via NF‑κB, STAT3 and COX‑2 pathways. Chronic inflammation creates a tumor‑promoting microenvironment that fuels resistance to DNA‑damaging chemotherapies and supports immune evasion. Repurposing FDA‑approved anti‑inflammatory drugs—NSAIDs, COX‑2 inhibitors and metformin—offers a rapid, cost‑effective way to boost chemotherapy, leveraging existing safety and pharmacokinetic data. Pre‑clinical studies show that indomethacin, naproxen, aspirin and celecoxib can sensitize diverse cancer cell lines, overcome multidrug resistance, and modulate apoptotic and cell‑cycle pathways. Hirschfeld Oncology embraces this strategy, integrating oncology, pharmacology, pathology and bioinformatics to identify optimal drug‑tumor pairings, design biomarker‑driven trials and deliver personalized combination regimens. By combining translational research, clinical trial expertise, and patient‑centered care, Hirschfeld Oncology aims to accelerate the adoption of evidence‑based anti‑inflammatory adjuncts across colorectal, pancreatic and breast cancers. The team’s framework includes surgeons, radiologists, data scientists and patient advocates, that each therapeutic decision reflects molecular insight and feasibility.

Inflammation, NSAIDs, and the Biology of Chemosensitization

Link between chronic inflammation and tumor progression Inflammation is a recognized hallmark of cancer, driving initiation, promotion, invasion, and metastasis. Persistent COX‑2‑mediated prostaglandin E2 production creates a pro‑survival milieu, activates NF‑κB and STAT3 pathways, and recruits immunosuppressive cells (MDSCs, TAMs), thereby fostering chemoresistance and metastatic spread.

Mechanisms by which NSAIDs modulate the tumor microenvironment NSAIDs such as indomethacin, naproxen, aspirin, and celecoxib inhibit COX‑2, lowering PGE2 levels and dampening NF‑κB/STAT3 signaling. This reduces anti‑apoptotic proteins (Bcl‑2), down‑regulates drug‑efflux pumps, and normalizes tumor interstitial fluid pressure, improving drug delivery. COX‑independent actions—including CDK‑2 inhibition, BCL‑2 family modulation, ROS generation, and mitochondrial targeting—further promote apoptosis and cell‑cycle arrest.

Key pre‑clinical findings for indomethacin and naproxen derivatives Hybrid indomethacin‑Pt(IV) prodrugs synergistically release cisplatin, achieving IC₅₀ 0.9–59.6 µM in cisplatin‑resistant lines and inducing G2/M arrest. Indomethacin‑methotrexate hybrids lower IC₅₀ to 10–16 µM against HeLa/MCF‑7 cells. Modified amide analogs (3a, 3b) show nano‑to‑micromolar IC₅₀ (0.055–4 µg mL⁻¹) and CDK‑2 inhibition. Naproxen‑copper(II) complexes (20d) kill cancer‑stem and bulk breast cancer cells (IC₅₀ ≈ 37 µM) and disrupt COX‑2. Organoselenium indomethacin/naproxen derivatives (7a, 34a, 34b) enhance cytotoxicity (IC₅₀ ≈ 8–12 µM) by increasing lipophilicity.

Cancer treatment chemotherapy Chemotherapy is a systemic cancer‑fighting treatment that uses powerful drugs to kill rapidly dividing cells, including malignant tumor cells. It can be administered alone or in combination with surgery, radiation, targeted therapy, or immunotherapy to improve cure rates, shrink tumors before other procedures, or eradicate microscopic disease after surgery. Depending on the clinical goal, chemotherapy may be curative, adjuvant, neoadjuvant, or palliative, and it is tailored by a medical oncologist to the patient’s specific cancer type, stage, and overall health. While effective, the drugs also affect normal fast‑growing tissues, leading to side effects such as fatigue, nausea, hair loss, and increased infection risk, which are managed with supportive care. At Hirschfeld Oncology, our multidisciplinary team integrates chemotherapy with innovative strategies and compassionate support to maximize outcomes for pancreatic and other cancers.

Indomethacin and Naproxen Derivatives: From Pain Relief to Tumor Killers

Hybrid molecules that couple indomethacin or naproxen with established chemotherapeutics (e.g., cisplatin, methotrexate) or metal centers (Pt(IV), Au(I), Zn(II), Cu(II)) have shown synergistic growth‑growth inhibition, induction of G2/M arrest, and reversal of cisplatin resistance in vitro. CDK‑2 inhibition is a recurring mechanism: amide‑modified indomethacin analogues (compounds 3a, 3b) and organoselenium derivatives (7a, 7b) suppress CDK‑2 activity, causing G1/S or G0/G1 arrest. Parallelly, BCL‑2 family modulation (up‑regulating Bax, down‑regulating BCL‑2) and mitochondrial targeting via triarylphosphonium‑indomethacin conjugates (16a‑d) drive apoptosis in breast cancer cells while sparing normal epithelium. Collectively indomethacin‑ and naproxen‑based hybrids exhibit broad antiproliferative potency across colorectal (HCT‑116, HT‑29, Caco‑2), breast (MCF‑7), pancreatic (BxPC‑3), prostate (PC‑3), hepatic (HepG2) and lung (A549) lines, with IC₅₀ values ranging from sub‑micromolar (0.055 µg mL⁻¹) to low‑micromolar (≈10 µM) concentrations.

List of repurposed drugs for cancer
Metformin, a widely used antidiabetic drug, has shown activity in inhibiting tumor growth and enhancing chemotherapy efficacy. Aspirin and other non‑steroidal anti‑inflammatory drugs, statins, and the immunomodulatory agent thalidomide are also being repurposed for their anti‑cancer and chemopreventive properties. Epigenetic modifiers such as valproic acid, metabolic agents like dichloroacetate, low‑dose naltrexone, and beta‑blockers have entered clinical trials as adjuncts in various solid‑tumor regimens. PDE‑5 inhibitors, chloroquine/hydroxychloroquine, clarithromycin, and doxycycline are explored for their ability to sensitize tumors to standard therapies and modulate the tumor microenvironment. Finally, antifungal agents itraconazole and mebendazole, all‑trans retinoic acid, and mTOR inhibitors are among the newer repurposed drugs showing promise in preclinical and early‑clinical studies.

Clinical Landscape: Trials, Outcomes, and Emerging Evidence

Latest cancer cure news Recent breakthroughs have turned once‑undruggable targets into viable therapies, most notably the FDA’s approval of KRAS‑directed drugs sotorasib and adagrasib, which show promise for KRAS‑mutant pancreatic, lung, and colorectal cancers. In 2025, researchers at UC San Francisco identified a druggable pocket on mutant K‑Ras, paving the way for next‑generation inhibitors currently in late‑stage trials. Immunotherapy advances at Memorial Sloan Kettering demonstrated that mismatch‑repair‑deficient tumors can be cleared without surgery or chemotherapy, offering a potential template for pancreatic cancer patients with similar biomarkers. Novel drug‑delivery techniques such as convection‑enhanced delivery are extending treatment reach into hard‑to‑penetrate tumors, hinting at future application for PD lesions. Together, these developments signal a rapid expansion of targeted and immune‑based cures that align with Hirschfeld Oncology’s mission to combine standard therapies with cutting‑edge strategies.

Drug repurposing for cancer therapy Drug repurposing leverages existing, clinically approved medications to uncover new anticancer activities, dramatically shortening development timelines and reducing costs. By targeting core hallmarks of cancer—such as uncontrolled proliferation, evasion of apoptosis, and angiogenesis—repurposed agents can act directly on tumor cells while also modulating the surrounding microenvironment to inhibit metastasis and drug resistance. Advanced computational screens, high‑throughput phenotypic assays, and data‑driven network analyses now enable rapid identification of promising candidates, many of which are being combined with nanotechnology‑based delivery systems to improve tumor specificity and minimize toxicity. In practice, these drugs are often integrated into combination regimens, enhancing the efficacy of standard chemotherapy, radiation, or immunotherapy without adding undue side‑effects. While challenges remain—including optimal dosing, regulatory pathways, and robust clinical validation—the growing evidence base positions drug repurposing as a powerful, science‑driven strategy for expanding therapeutic options for pancreatic and other hard‑to‑treat cancers.

Drug repurposing for cancer treatment – a comprehensive review Comprehensive reviews highlight that repurposed agents span diverse pharmacological classes, including antihypertensives, antidiabetics, antifungals, and psychiatric drugs, and can be grouped by multi‑type activity, cancer‑type specificity, or mechanism‑directed action such as inhibition of angiogenesis, DNA repair, or immune modulation. Leveraging known safety profiles accelerates pre‑clinical validation and clinical trial initiation, often within combination regimens or nanotechnology‑enhanced delivery systems that improve tumor targeting and reduce toxicity. Successful examples include metformin’s metabolic reprogramming in breast and pancreatic cancers, thalidomide’s anti‑angiogenic effects in multiple myeloma, and the antimalarial artesunate’s pro‑oxidant activity in colorectal and lung tumors. Ongoing challenges involve rigorous biomarker‑driven patient selection, regulatory pathways, and integration with precision‑medicine platforms, but the field’s momentum promises a steady pipeline of novel, affordable anticancer therapies.

Synergistic Strategies: NSAIDs Plus Standard Chemotherapy

Molecular mechanisms of synergy NSAIDs suppress COX‑2‑driven prostaglandin E2, lowering NF‑κB and STAT3 signaling that otherwise promote survival and drug‑efflux. In vitro, indomethacin‑derived Pt(IV) prodrugs and copper(II)‑naproxen complexes down‑regulate BCL‑2, up‑regulate Bax and inhibit ATP‑dependent efflux pumps, restoring intracellular cisplatin or 5‑FU levels and achieving 8‑23‑fold potency gains across colon, lung and breast lines. Hybrid agents Indomethacin‑methotrexate hybrids (IC₅₀ ≈ 10‑16 µM) outperform either parent drug, while naproxen‑copper(II) complexes eradicate cancer stem cells at ~37 µM and cripple migration. Organoselenium and triarylphosphonium conjugates further increase lipophilicity and mitochondrial targeting, yielding sub‑micromolar IC₅₀s against breast and colorectal cancers. Impact on tumor microenvironment and metastasis NSAID‑based regimens lower COX‑2‑mediated inflammation, reduce MDSC infiltration, and normalize tumor interstitial fluid pressure, improving chemotherapy penetration. Hybrid naproxen‑podophyllotoxin and indomethacin‑podophyllotoxin conjugates specifically curb angiogenesis and invasiveness of drug‑resistant hepatocellular carcinoma.

Cancer Care: The Role of Repurposed drugs and Metabolic Interventions in treating Cancer Repurposed agents are FDA‑approved drugs with known safety that exhibit anticancer activity by targeting metabolism (e.g., metformin, statins) or signaling (e.g., β‑blockers). Metabolic strategies such as ketogenic diets or intermittent fasting starve tumor cells and trigger ferroptosis, sensitizing them to surgery, radiation, or chemotherapy. Ongoing trials are validating these low‑cost adjuncts for personalized care.

Repurposed drugs for breast cancer Metformin inhibits mTOR and cancer‑stem‑cell growth; ivermectin blocks STAT3 and induces apoptosis in triple‑negative disease; sertraline and thioridazine suppress ER signaling and reverse ABC‑transporter‑mediated resistance. Celecoxib and propranolol add COX‑2 inhibition and angiogenesis blockade, respectively, enhancing standard chemotherapy efficacy.

Repurposed drugs for colon cancer Propranolol attenuates catecholamine‑driven proliferation; etodolac (COX‑2 inhibitor) reduces prostaglandin‑mediated growth and postoperative spread. The COMPIT trial showed peri‑operative propranolol + etodolac cut five‑year recurrence from 50 % to 12.5 %. Metformin, aspirin, and statins are also under investigation for metabolic and inflammatory targeting.

Pancreatic Cancer Focus: Anti‑Inflammatory Repurposing in a Hard‑to‑Treat Disease

Inflammation‑driven chemoresistance in PDAC Chronic inflammation is a hallmark of pancreatic ductal adenocarcinoma, fueling NF‑κB, STAT3 and COX‑2 pathways that enhance tumor survival, stromal desmoplasia and drug‑efflux pump activity. This inflammatory milieu diminishes the efficacy of gemcitabine and FOLFIRINOX by promoting cancer‑stem‑cell maintenance and immune‑suppressive myeloid‑derived suppressor cells.

Indomethacin‑based Pt(IV) prodrugs and naproxen‑copper complexes Hybrid agents that marry NSAID scaffolds with metal centers have shown promise in overcoming resistance. Indomethacin‑Pt(IV) prodrugs release cisplatin and indomethacin intracellularly, achieving IC₅₀ values of 0.91‑59.6 µM in cisplatin‑resistant lines and inducing G2/M arrest. Naproxen‑Cu(II) complexes (e.g., 20d) eradicate cancer‑stem cells and bulk breast cancer cells at ~37 µM, while down‑regulating COX‑2 and disrupting mitochondrial function, suggesting a dual anti‑inflammatory/anticancer mechanism.

Clinical trial data and future directions Phase II studies have combined COX‑2 inhibitors (celecoxib) with gemcitabine‑based regimens, reporting modest tumor‑size reductions and improved progression‑free survival. Low‑dose aspirin during adjuvant chemotherapy correlates with better overall survival in PDAC cohorts. Ongoing trials (e.g., NCT03021723) evaluate NSAIDs in peri‑operative settings, and nanocarrier‑mediated delivery of NSAID‑metal hybrids aims to increase tumor selectivity while limiting gastrointestinal toxicity. Biomarker‑driven designs—targeting COX‑2 overexpression or NF‑κB activation—will refine patient selection.

Answer to "Drug repurposing pancreatic cancer" Drug repurposing—identifying new anticancer uses for already‑approved medicines—has become a key strategy for tackling pancreatic cancer’s poor prognosis and limited therapeutic options. By leveraging existing safety data, researchers can rapidly test agents such as metformin, statins, and hydroxychloroquine, which have shown promise in preclinical models by targeting metabolic and autophagy pathways common to pancreatic tumors. Recent studies also highlight novel mechanisms, for example the discontinued compound PRLX‑93936, which acts as a molecular glue to degrade the nuclear pore complex via TRIM21, leading to tumor cell death in animal models. Clinical trials are now evaluating these repurposed drugs alone or in combination with standard chemotherapy to improve response rates and reduce toxicity. This approach offers a faster, cost‑effective pathway to expanding treatment options for pancreatic cancer patients while maintaining a strong scientific foundation.

Answer to "Latest cancer cure news" Recent breakthroughs have turned once‑undruggable targets into viable therapies, most notably the FDA’s approval of KRAS‑directed drugs sotorasib and adagrasib, which show promise for KRAS‑mutant pancreatic, lung, and colorectal cancers. In 2025, researchers at UC San Francisco identified a druggable pocket on mutant K‑Ras, paving the way for next‑generation inhibitors currently in late‑stage trials. Immunotherapy advances at Memorial Sloan Kettering demonstrated that mismatch‑repair‑deficient tumors can be cleared without surgery or chemotherapy, offering a potential template for pancreatic cancer patients with similar biomarkers. Novel drug‑delivery techniques such as convection‑enhanced delivery are extending treatment reach into hard‑to‑penetrate tumors, including diffuse intrinsic pontine glioma, hinting at future applications for pancreatic lesions. Together, these developments signal a rapid expansion of targeted and immune‑based cures that align with Hirschfeld Oncology’s mission to combine standard therapies with cutting‑edge strategies.

Metabolic and Nutritional Adjuncts: Vitamins, Diet, and Unconventional Agents

Vitamin D is commonly referred to as the “cancer‑fighting vitamin.” It regulates cell growth, promotes differentiation, and reduces inflammation, all of which help prevent the development of malignant cells. Deficiencies in vitamin D have been associated with higher risks of colon, prostate, breast, and ovarian cancers. Adequate levels are typically achieved through sunlight exposure, dietary sources such as fatty fish, and supplementation when needed. Maintaining optimal vitamin D status is therefore considered an important component of cancer prevention and supportive oncology care.

Fenbendazole, a veterinary anthelmintic, has attracted interest for its possible anticancer properties, but it has never been approved for human use and lacks robust clinical data. Pre‑clinical studies suggest it can disrupt microtubule formation and may sensitize tumor cells, raising the hypothesis that it could enhance chemotherapy’s effectiveness or allow lower chemo doses. However, evidence from case reports is anecdotal, and a recent case‑series claiming remission was later retracted, underscoring the uncertainty of its safety and benefit. Because the drug’s dosing, pharmacokinetics, and interaction with standard chemotherapies are not well understood, patients should not use fenbendazole without direct supervision from their oncology team.

Mebendazole, a low‑cost anthelmintic listed on the WHO’s Essential Medicines, has shown promising anticancer activity in pre‑clinical prostate‑cancer models. Laboratory studies demonstrate that, when combined with the standard chemotherapy drug docetaxel, mebendazole enhances tumor‑cell killing by disrupting microtubule dynamics and the molecular scaffold required for cell division. In mouse models, this combination halted prostate‑tumor growth and increased cancer‑cell apoptosis without adding significant toxicity. Although these findings are encouraging, clinical data are still limited, and well‑designed trials are needed to confirm optimal dosing, safety, and efficacy in patients. If validated, mebendazole could become an inexpensive, readily available adjunct to existing prostate‑cancer therapies.

Antifungal Agents as Unexpected Oncology Tools

The provided source material focuses on non‑steroidal anti‑inflammatory drugs (NSAIDs), cardiovascular agents, and related repurposing strategies for cancer therapy. It does not contain information about antifungal agents such as itraconazole or clotrimazole, nor does it discuss their off‑target anticancer pathways, pre‑clinical efficacy in pancreatic or other solid tumors, or translational challenges and trial design considerations. Consequently, I cannot generate a content‑based section on repurposing antifungal drugs for cancer therapy using the supplied sources.

Cardiovascular and Metabolic Repurposing: Metformin, Statins, and Beta‑Blockers

Metformin activates AMP‑activated protein kinase (AMPK), which in turn suppresses mTOR signaling, curbing protein synthesis and cancer‑stem‑cell proliferation. In breast cancer, metformin’s AMPK‑driven mTOR inhibition synergizes with chemotherapy, enhancing apoptosis and reducing drug resistance. Statins exert anti‑inflammatory actions by lowering cholesterol‑derived isoprenoids that activate oncogenic pathways; they also inhibit DNA methyltransferases, leading to re‑expression of tumor‑suppressor genes and impaired tumor growth. Beta‑blockers, particularly propranolol, modulate the tumor microenvironment by decreasing adrenergic‑driven angiogenesis and immune‑suppressive cell recruitment, thereby improving chemosensitivity.

Drug repurposing for breast cancer leverages approved medicines to target growth, resistance, and the microenvironment. Metformin blocks mTOR and reduces cancer‑stem‑cell activity; ivermectin inhibits STAT3‑ sertraline suppresses estrogen‑receptor signaling; thioridazine reverses multidrug resistance via ABC‑transporter modulation. NSAIDs such as celecoxib and cardiovascular agents like propranolol add COX‑2 inhibition and angiogenesis blockade. Ongoing trials combine these agents with standard chemotherapy to raise response rates and curb relapse across breast‑cancer subtypes.

Drug repurposing for pancreatic cancer focuses on agents with metabolic and anti‑inflammatory effects. Metformin, statins, and hydroxychloroquine target metabolic pathways and autophagy, improving chemotherapy efficacy. Emerging compounds, e.g., PRLX‑93936, degrade nuclear‑pore proteins, inducing tumor death. Clinical studies now test these repurposed drugs alone or with gemcitabine‑based regimens, aiming to boost response, lower toxicity, and provide faster, cost‑effective treatment options for this aggressive malignancy.

Immune Checkpoint Blockade Meets Anti‑Inflammatory Therapy

Immunotherapy cancer treatment
Immunotherapy harnesses the patient’s own immune system to recognize and destroy cancer cells. The most widely used class are immune‑checkpoint inhibitors (ICIs) that block inhibitory receptors such as PD‑1, PD‑L1, or CTLA‑4, releasing T‑cells to attack tumors. Other modalities include CAR‑T cells, cancer vaccines, oncolytic viruses and immune‑modulating agents. Over 40 ICIs are FDA‑approved for more than 30 tumor types, and they are increasingly combined with chemotherapy, radiation, or targeted drugs to improve response rates and durability of benefit.

COX‑2 inhibition to improve checkpoint response
Pre‑clinical studies show that selective COX‑2 inhibitors (e.g., celecoxib) suppress prostaglandin E2 production, dampen NF‑κB/STAT3 signaling, and lower immunosuppressive cytokines, thereby reversing tumor‑driven immune evasion. In mouse models, celecoxib raised checkpoint‑inhibitor response from <30 % to ~70 % and eradicated many tumours. Early clinical work (the LION trial) is testing celecoxib plus PD‑1/PD‑L1 blockade in lung, kidney and breast cancers, reflecting a growing consensus that COX‑2 inhibition can convert “cold” tumours into “hot” ones amenable to immunotherapy.

Milestone discoveries and the "miracle" drug
A landmark breakthrough is the PD‑1 inhibitor dostarlimab, celebrated as a “miracle” drug for mismatch‑repair‑deficient or microsatellite‑instability‑high colorectal cancer. Patients receiving dostarlimab achieved complete clinical responses without surgery, radiation or chemotherapy, illustrating the power of checkpoint re‑activation in a genetically defined subset. Parallel milestone discoveries include FDA approvals of KRAS‑targeted agents (sotorasib, adagrasib) and the emerging use of nano‑delivered NSAIDs to boost chemo‑immunotherapy efficacy. Together, these advances underscore a paradigm shift: integrating anti‑inflammatory agents—particularly COX‑2 blockers—into checkpoint‑inhibitor regimens to amplify anti‑tumor immunity while preserving patient safety.

Practical Chemotherapy Scheduling: Rules, Radiobiology, and Optimizing Outcomes

What is the rule of 7 in chemotherapy?
The rule of 7 describes a weekly dosing pattern in which a chemotherapeutic agent is administered on 1–5 consecutive days, followed by a two‑day rest to complete a seven‑day cycle. After this short micro‑rest, patients typically receive a longer interval—often 3–4 weeks—to allow bone‑marrow and immune recovery before the next cycle begins. This schedule balances sustained drug exposure for tumor cells with a brief recovery window for normal tissues, helping to control toxicity while preserving efficacy. It is a practical framework for many solid‑tumor regimens, including pancreatic cancer protocols used at Hirschfeld Oncology.

What are the 4 R’s of cancer?
The 4 R’s of radiobiology—Repair, Redistribution, Repopulation, and Reoxygenation—govern the success of radiation treatment. Repair refers to normal tissue’s ability to fix sub‑lethal DNA damage; Redistribution denotes cell‑cycle progression that may render tumor cells more radiosensitive; Repopulation describes tumor regrowth between fractions; and Reoxygenation improves oxygen‑mediated DNA damage in previously hypoxic tumor regions. Understanding these processes guides fractionation and dose‑intensity decisions.

Most effective cancer treatment
The most effective approach is individualized, integrating surgery, radiation, chemotherapy, targeted agents, and immunotherapy based on tumor type, stage, molecular profile, and patient health. For pancreatic cancer, surgical resection followed by adjuvant chemotherapy (often gemcitabine‑based) and/or chemoradiation is standard. Biomarker‑driven therapies—such as COX‑2 inhibitors or NSAID‑derived hybrids that sensitize tumors to chemotherapy—are emerging adjuncts. Ultimately, a multidisciplinary team tailors a coordinated, evidence‑based plan that maximizes tumor control while minimizing toxicity.

Conclusion

Anti‑inflammatory drugs—particularly NSAIDs such as indomethacin, naproxen, aspirin, and COX‑2 inhibitors—have emerged as compelling chemo‑sensitizers in pre‑clinical studies and early clinical observations. Their ability to modulate tumor‑associated inflammation, down‑regulate NF‑κB/STAT3 pathways, improve drug delivery, and overcome multidrug resistance offers a cost‑effective avenue to boost the efficacy of existing chemotherapeutics. However, the heterogeneous outcomes of recent randomized trials underscore the necessity for rigorously designed studies that incorporate biomarker‑driven patient selection, optimal dosing schedules, and safety monitoring. Hirschfeld Oncology remains dedicated to translating these insights into practice through multidisciplinary collaboration, precision‑medicine approaches, and innovative delivery platforms, all while prioritizing patient safety and individualized care. By integrating scientifically vetted anti‑inflammatory agents into combination regimens, the institute aims to advance oncology therapeutics and improve outcomes for patients across diverse cancer types.